12:00 AM
Dec 10, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Status

TD-9855: Phase II started

Theravance began a placebo-controlled, double-blind, U.S. Phase II trial to evaluate 2 doses of once-daily TD-9855 for up to 9 weeks in...

Read the full 88 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >